AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03658291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sanjin tablets simulants
Description: levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
Study NCT03658291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
Study NCT03013400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebselen
Description: Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
Study NCT03013400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo is identical in appearance to the ebselen capsules
Study NCT01608165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment for renal mass
Description: Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
Study NCT01608165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Radiofrequency ablation
Description: Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
Study NCT01608165 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparascopic or percutaneous cryoablation
Description: Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
Study NCT00003537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01868646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subetta
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study NCT01868646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study NCT02208908 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the oral conditionand proper care
Description: An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
Study NCT02915939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Residential Care Transition Module
Description: Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
Study NCT02737267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderately high protein diet
Description: After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.
Study NCT02737267 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low fat diet
Description: After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat
Study NCT00571675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101, prednisone and docetaxel
Description: docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
Study NCT00571675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, prednisone and docetaxel
Description: docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
Study NCT03449251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Study NCT02719977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX5461
Study NCT04574089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Baofukang Suppository 7 days
Description: Experimental: Baofukang Suppository 7 days
Study NCT04574089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Baofukang Suppository 14 days
Description: Experimental: Baofukang Suppository 14 days
Study NCT01288690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: 3, 1-1/2 hour sessions, individual, meeting weekly.
Study NCT03092427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dietary Supplement
Study NCT03092427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03759080 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mental practice
Description: training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
Study NCT03759080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive neuromuscular facilitation
Description: upper limb Pattern: Flexion -Abduction- External rotation
Study NCT03175796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Mental Health-Home Visiting
Description: Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
Study NCT03982524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
Study NCT03982524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
Study NCT01994213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib 25 mg p.o. qd
Study NCT00596219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: celecoxib
Study NCT02672241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
Study NCT02672241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
Study NCT01748370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in hypogonadal men
Study NCT01748370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in eugonadal men
Study NCT01748370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hypogonadal
Study NCT01748370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eugonadal
Study NCT01629550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin disinfection prior catheter insertion
Study NCT04126434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mask
Description: facemask
Study NCT04126434 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: mask
Description: facemask
Study NCT01346865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid
Study NCT01346865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tablet bid
Study NCT01719380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study NCT01719380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT01719380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT01611675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: take orally, twice daily
Study NCT01611675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: take orally, once daily
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fMRI imaging
Description: Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [11C]carfentanil PET scan
Description: \[11C\]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [18F]FMPEP-d2 PET scan
Description: \[18F\]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: [18F]-FDG PET scan
Description: Brain and body insuin stimulated glucose uptake is measured with radioligand \[18F\]-FDG.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity measures and fitness tests
Description: Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory measurements
Description: Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
Study NCT03106688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic euglycemic clamp
Description: Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
Study NCT00974311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: MDV3100, 160 mg orally per day
Study NCT00974311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT04474340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalscent Plasma
Description: The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
Study NCT03155711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC group
Description: Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
Study NCT03155711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: Supplemental oxygen through venturi mask
Study NCT03158207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waters Mask
Description: All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
Study NCT03158207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mask
Description: Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
Study NCT03102762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
Study NCT03102762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
Study NCT03326440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VERT system
Description: 3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
Study NCT00663650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Section Control
Description: After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
Study NCT00663650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Section Control
Description: After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
Study NCT02904746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make It!
Description: The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
Study NCT02654639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 Twice a day by mouth day 1-5 and 8-12
Study NCT02654639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion once every 14 days
Study NCT01248897 — intervention group
Intervention type: OTHER
Intervention: This study is non-interventional study, so this section is not applicable.
Description: This study is non-interventional study, so this section is not applicable.
Study NCT03691636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyelash prostheses
Description: Eyelash prostheses are essentially specialized eyelash extensions
Study NCT03691636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5.0% Lifitegrast Ophthalmic Solution
Description: 5.0% Lifitegrast Ophthalmic Solution
Study NCT03318263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: next-generation sequencing (NGS)
Description: ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
Study NCT05022498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 min treadmill exercise performed at 60% of maximum oxygen uptake.
Study NCT00960193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
Study NCT00960193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
Study NCT00960193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seville Orange Juice
Description: 240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
Study NCT02938468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02938468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any surgical intervention aim at treating chronic subdural hematoma
Study NCT01324102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga therapy
Description: For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
Study NCT02501824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthroposophic therapeutic speech
Description: anthroposophic therapeutic speech
Study NCT01210638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone
Description: 10 mg tablet
Study NCT02888834 — intervention group
Intervention type: OTHER
Intervention: Adverse drug reaction
Study NCT04221334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electric Toothbrush
Description: Electric Toothbrush used to remove dental plaque and resolve gingivitis
Study NCT04221334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral health care application
Description: phone application that shows the user brushing efficiency real time
Study NCT02560168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoVista device
Description: MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device